Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A compound of formula (**I**):



(I)

wherein:

R^1 is halo, cyano, C_{1-3}alkyl or C_{1-3}alkoxy;

p is 0-2; wherein the values of R^1 may be the same or different;

R^2 is hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, a heterocyclyl or heterocyclylC_{1-3}alkyl; wherein R^2 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^3 is hydrogen, halo or cyano;

R^4 is C_{2-6}alkyl or C_{1-6}alkoxyC_{1-6}alkyl;

R^5 is C_{1-6}alkyl or C_{2-6}alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;

R^6 is C_{1-4}alkyl;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 2 (currently amended): The compound of formula **(I)** according to claim 1 wherein p is 0; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 3 (currently amended): The compound of formula **(I)** according to claim 1 wherein R^2 is hydrogen or C_{1-4}alkyl; wherein R^2 may be optionally substituted on carbon by one or more methoxy or ethoxy; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 4 (currently amended): The compound of formula **(I)** according to claim 1 wherein R^3 is hydrogen; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 5 (currently amended): The compound of formula **(I)** according to claim 1 wherein R^4 is C_{2-4}alkyl; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 6 (currently amended): The compound of formula **(I)** according to claim 1 wherein R^5 is C_{1-6}alkyl; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 7 (currently amended): The compound of formula **(I)** according to claim 1 wherein R^6 is methyl; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 8 (currently amended): The compound of formula **(I)** according to claim 1 wherein:
p is 0;

R^2 is hydrogen, 2-methoxyethyl, methyl, 3-methoxypropyl or 2-ethoxyethyl;

R^3 is hydrogen;

R^4 is ethyl or isopropyl;

R^5 is methyl or ethyl;

R^6 is methyl;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 9 (currently amended): The compound of formula **(I)** according to claim 1 selected from:

4-(1,2-diethyl-4-methylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino} pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino} pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[*N*-(3-methoxypropyl)sulphamoyl]anilino} pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino} pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[*N*-(methyl)sulphamoyl]anilino}pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-(4-sulphamoylanilino)pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino} pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[*N*-(3-methoxypropyl)sulphamoyl]anilino} pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-(4-sulphamoylanilino)pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino} pyrimidine; or

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[*N*-(methyl)sulphamoyl]anilino}pyrimidine;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 10 (currently amended): A process for preparing a compound of formula **(I)** or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof ~~as claimed in~~ according to claim 1, which process (wherein R^1, R^2, R^3, R^4, R^5, R^6 and p are, unless otherwise specified, as defined in claim 1) comprises of:

Process a) reaction of a pyrimidine of formula **(II)**:



(II)

wherein L is a displaceable group; with an aniline of formula **(III)**:



(III)

or

Process b) reacting a compound of formula **(IV)**:



(IV)

with a compound of formula **(V)**:



(V)

wherein T is O or S; R^x may be the same or different and is C_{1-6}alkyl;

or

Process c) reacting a pyrimidine of formula **(VI)**:



(VI)

wherein X is a displaceable group; with an amine of formula **(VII)**:

R^2-NH_2

(VII)

or

Process d) reacting a pyrimidine of formula **(VIII)**



(VIII)

with a compound of formula **(IX)**:



(IX)

where Y is a displaceable group;

and thereafter, optionally:

i) converting a compound of the formula **(I)** into another compound of the formula **(I)**;

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~.

Claim 11 (currently amended): A pharmaceutical composition which comprises a compound of the formula **(I)**, or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, according to claim 1, in association with a pharmaceutically-acceptable diluent or carrier.

Claim 12-23 (cancelled)

Claim 24 (currently amended): A method of treating ~~cancer~~ rheumatoid arthritis in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt ~~or *in*~~

~~*v.i.z.* hydrolysable ester~~ thereof ~~as claimed in~~ according to claim 1.

Claim 25 (cancelled)